$69B CVS-Aetna deal may get regulatory approval soon

Amy Baxter | | Health Exec | Policy & Regulations

CVS Health’s $69 billion takeover of Aetna may soon be greenlit by the U.S. Department of Justice Antitrust Division, according to Reuters, which cited a source familiar with the matter.

The deal brings together one of the nation’s biggest pharmacy retailers and a major health insurance provider.

However, approval may not come in September, according to the source. CVS may need to arrange divestitures to resolve antitrust concerns that may take some time, Reuters reported. 

Another major deal in healthcare was approved by federal regulators earlier this week. Cigna’s $67 billion purchase of Express Scripts cleared the DOJ but still needs regulatory approval from several states.

The CVS deal is being closely watched as one of the most transformative transactions, bringing major industry consolidation. The deal was originally announced at the end of 2017 and is expected to close sometime in the second half of 2018, pending regulatory approval.

See the full story below:

U.S. review of CVS deal for Aetna may end soon: source

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

4 points crucial to the nimble regulation of GenAI
FDA recalls infant incubators due to risk of door falling off
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT
Kentucky AG launches criminal probe after conscious man nearly has organs harvested
FDA announces Class I recall of ventilators after 3 patient injuries
FDA clears AI tool that flags signs of heart disease in chest CT scans

Around the web

AI in Healthcare
4 points crucial to the nimble regulation of GenAI

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Design by Adaptive Theme
Trimed Popup
Trimed Popup